Analysts’ Top Healthcare Picks: Pfizer (PFE), EDAP TMS (EDAP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE – Research Report), EDAP TMS (EDAP – Research Report) and Aptinyx (APTX – Research Report) with bullish sentiments.

Pfizer (PFE)

In a report released today, Colin Bristow from UBS maintained a Buy rating on Pfizer, with a price target of $59.00. The company’s shares closed last Thursday at $47.90.

According to TipRanks.com, Bristow ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.4% and a 38.6% success rate. Bristow covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, Merck & Company, and Bristol Myers.

Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $56.45.

See Insiders’ Hot Stocks on TipRanks >>

EDAP TMS (EDAP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on EDAP TMS, with a price target of $11.00. The company’s shares closed last Thursday at $8.29.

According to TipRanks.com, Ramakanth ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.8% and a 32.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Janux Therapeutics Inc, and Corcept Therapeutics.

Currently, the analyst consensus on EDAP TMS is a Moderate Buy with an average price target of $11.00.

Aptinyx (APTX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aptinyx today and set a price target of $1.00. The company’s shares closed last Thursday at $0.40, close to its 52-week low of $0.33.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -28.7% and a 23.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Aquestive Therapeutics.

Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $2.00, implying a 412.8% upside from current levels. In a report issued on August 15, BMO Capital also assigned a Buy rating to the stock with a $2.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PFE:

• Issue of Equity (DRIS)
• H.C. Wainwright Sticks to Their Buy Rating for Century Therapeutics (IPSC)
• Pfizer (PFE) Receives a Hold from Barclays
• H.C. Wainwright Sticks to Their Buy Rating for Arcadia Biosciences (RKDA)
• Website Traffic Continues to Rise for Marriott Vacations (NYSE:VAC): Here’s What it Means